Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation

A Attar, M Lémann, A Ferguson, M Halphen, M C Boutron, B Flourié, E Alix, M Salmeron, F Guillemot, S Chaussade, A M Ménard, J Moreau, G Naudin, M Barthet, A Attar, M Lémann, A Ferguson, M Halphen, M C Boutron, B Flourié, E Alix, M Salmeron, F Guillemot, S Chaussade, A M Ménard, J Moreau, G Naudin, M Barthet

Abstract

Background: Polyethylene glycol (PEG) 3350 is a non-absorbable, non-metabolised osmotic agent used in lavage solutions for gut cleansing.

Aims: To compare the efficacy of PEG and lactulose in chronic constipation.

Methods: A total of 115 patients with chronic constipation entered a multicentre, randomised, comparative trial. They initially received two sachets containing either PEG (13 g/sachet) or lactulose (10 g/sachet) and were given an option to change the dose to one or three sachets/day, depending on response.

Results: Ninety nine patients completed the trial. After four weeks, patients in the PEG group (n=50) had a higher number of stools and a lower median daily score for straining at stool than patients in the lactulose group (n=49). Overall improvement was greater in the PEG group. Clinical tolerance was similar in the two groups, but flatus was less frequently reported in the PEG group. The mean number of liquid stools was higher in the PEG group but the difference was significant only for the first two weeks. There were no serious adverse events and no significant change in laboratory tests in either group. At the end of the study, the number of sachets used by the patients was 1.6 (0.7)/day in the PEG group and 2.1 (0.7)/day in the lactulose group. Sixty one patients completed a further two months open study of one to three sachets PEG daily; there was no loss of efficacy and no serious toxicity.

Conclusion: Low dose PEG 3350 was more effective than lactulose and better tolerated.

Figures

Figure 1
Figure 1
Clinical tolerance of PEG (black bars) and lactulose (white bars). The percentage of patients with a median daily score greater than 1 was significantly lower in the PEG group for bloating (p

Figure 2

Percentage of patients taking the…

Figure 2

Percentage of patients taking the different dosages of PEG (black bars) and lactulose…

Figure 2
Percentage of patients taking the different dosages of PEG (black bars) and lactulose (white bars) during the last two weeks of the study.
Figure 2
Figure 2
Percentage of patients taking the different dosages of PEG (black bars) and lactulose (white bars) during the last two weeks of the study.

References

    1. J Am Pharm Assoc Am Pharm Assoc. 1955 Jan;44(1):27-30
    1. Am J Med. 1990 Nov;89(5):597-601
    1. Am J Gastroenterol. 1990 Mar;85(3):261-5
    1. J Clin Invest. 1989 Oct;84(4):1056-62
    1. J Am Geriatr Soc. 1978 May;26(5):236-9
    1. Gastroenterology. 1986 Jun;90(6):1914-8
    1. Age Ageing. 1986 May;15(3):182-4
    1. J Clin Invest. 1985 Feb;75(2):608-13
    1. Am J Gastroenterol. 1982 Sep;77(9):599-603
    1. Drugs. 1980 Jan;19(1):49-58
    1. Dig Dis Sci. 1995 Feb;40(2):349-56
    1. Z Gastroenterol. 1995 Jan;33(1):5-8
    1. Lancet. 1994 Jul 2;344(8914):39-40
    1. Aliment Pharmacol Ther. 1994 Aug;8(4):391-5
    1. BMJ. 1993 Sep 25;307(6907):769-71
    1. Aliment Pharmacol Ther. 1993 Oct;7(5):523-9
    1. Dig Dis Sci. 1996 Aug;41(8):1636-42

Source: PubMed

3
Subskrybuj